Jalna

Researchers are evaluating the safety and potential benefits of a new stem cell treatment called Eyecyte-RPE12 for patients with Geographic Atrophy (GA) caused by dry Age-related Macular Degeneration (d-AMD). GA is a progressive eye disease leading to vision loss, and currently, there are no approved treatments that can restore the damaged retinal cells. This study is a Phase 1/2a trial conducted in India using an indigenously developed stem cell therapy. Participants will receive a single dose of Eyecyte-RPE12 through a subretinal injection in the affected eye. The treatment consists of retinal pigment epithelial cells derived from human induced pluripotent stem cells. The study includes dose escalation and closely monitors safety and efficacy through advanced imaging techniques such as Fundus Autofluorescence. The progression of GA and the effects of the treatment will be followed for up to 12 months. During the study, participants will undergo detailed eye exams, imaging, and vision assessments including Best Corrected Visual Acuity measurements. Researchers will track safety, tolerability, and any changes in retinal health using Fundus Autofluorescence imaging. Participants must be able to attend all clinic visits and complete study procedures, including anesthesia and vitrectomy required for the injection. The study will also monitor for any adverse effects and overall vision outcomes over the course of the trial.